Yidu Tech has announced its financial results for the fiscal year ending March 31, 2026. The group achieved revenue of RMB819 million, representing a year-on-year increase of 14.6%. The profit attributable to the company's owners was RMB72.709 million, marking a successful shift from loss to profit compared to the previous year. Basic earnings per share were RMB0.07, and the company proposed a final dividend of HK$0.04 per share.
The global medical artificial intelligence industry is entering a new phase characterized by technological maturity, practical implementation, and the realization of industrial value. The iteration of large model technology, the integration of multimodal data, and deep combination with real-world medical scenarios are driving structural development opportunities within the sector. Medical AI is accelerating its evolution from single-point tool applications towards empowering the entire clinical workflow, providing comprehensive industry chain services, and enabling full-cycle health management. This progression continues to address critical industry pain points such as the uneven distribution of high-quality medical resources, insufficient clinical research efficiency, and the need for improvement in public health security systems.
As a core enterprise in China's medical AI sector, YIDU TECH (02158) has long been dedicated to the deep integration of artificial intelligence and the healthcare industry. Leveraging years of accumulated experience in medical scenarios and continuous breakthroughs in proprietary AI technology, the company has established an intelligent ecosystem layout covering the entire "medical-pharmaceutical-insurance-patient" chain. The group has consistently maintained a focused strategy, deepening relationships with core clients and key business areas. During the reporting period, it successfully achieved a historic transition from operating at a loss to generating a profit. Against a backdrop of favorable industry policies and rapidly accelerating demand for AI in healthcare, the group saw improvements in both the scale of its orders and the quality of its revenue.
As of March 31, 2026, the group's total revenue reached RMB819 million, a 14.6% increase year-on-year, while its gross profit margin improved from 33.5% to 36.4%. More significantly, through the continuous optimization of its cost structure and enhanced operational synergy across business segments, the group achieved an annual profit of RMB78.8 million, signifying its entry into a new stage of operations.
Regarding cash flow, the net cash outflow from operating activities for the full year narrowed significantly by 91.2%. Notably, the net cash flow from operating activities turned positive in the second half of the year, reaching RMB29.3 million. These results validate the core competitiveness of the company's technology and products within the industry and lay a solid foundation for sustained, high-quality growth in the future.
During the reporting period, the group continued to enhance the YiduCore's capabilities in understanding disease mechanisms, clinical decision-making pathways, and real-world diagnosis and treatment behaviors. By March 31, 2026, YiduCore had cumulatively processed and analyzed nearly 9 billion authorized real-world medical records, covering over 1.32 billion patient encounters. Its specialized disease databases now cover more than a hundred disease types, and its disease knowledge graph essentially encompasses all known diseases.
In the AI for Medical (big data platform and solutions) segment, as of March 31, 2026, the group provided solutions to 133 top-tier hospitals in China and 54 regulatory agencies and policymakers, covering more than 12,000 hospitals. Key products, including the AI Middle Platform 3.0, Clinical Assistant Copilot 2.0, Yidu Zhi Xun, Yidu Zhi Guan, and high-quality dataset solutions based on specialized research databases, were fully implemented and deployed during the period. Notably, the Medical Intelligence Agent has been comprehensively rolled out, propelling the concept of the AI Hospital towards reality.
In the AI for Life Sciences (life sciences solutions) segment, the number of life sciences clients served by the group reached 98. Among the top 20 multinational pharmaceutical companies, 17 are clients of the group. In clinical research, the group has completed 516 clinical studies, including both sponsor-initiated trials and investigator-initiated trials. The number of prospective and retrospective real-world research projects reached 320.
In the AI for Care (health management platform and solutions) segment, the group maintained a leading position in the惠民保 (Hui Min Bao) business within first-tier cities. It served as the primary operating platform for "Shenzhen Hui Min Bao" for the fourth consecutive year, with the number of insured participants exceeding 6 million for three straight years. It also continued as the primary operating platform for "Beijing Hui Min Bao" for the fifth consecutive year, with cumulative participation surpassing 19 million person-times. The number of active users who completed at least one transaction on the group's health management platform exceeded 22 million.
Comments